Table of Contents

ASCITES: AETIOLOGY, SYMPTOMS AND TREATMENT; ASCITES: AETIOLOGY, SYMPTOMS AND TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: ASCITES IN HUMAN LIVER CIRRHOSIS; ABSTRACT; LIVER CIRRHOSIS; CLINICAL EVOLUTION OF LIVER CIRRHOSIS; Ascites; BACTERIAL TRANSLOCATION; SPONTANEOUS BACTERIAL PERITONITIS; INTESTINAL MICROBIOTA ALTERATIONS IN CIRRHOTIC PATIENTS; PERITONEAL HOST DEFENSE MECHANISMSIN HEALTHY INDIVIDUALS; ALTERATIONS IN PERITONEAL IMMUNERESPONSE IN CIRRHOSIS; Alterations at Cellular Level; Alterations at Molecular Level INCREASED INTESTINAL PERMEABILITY LEADSTO EXHAUSTION OF THE IMMUNE SYSTEMPITFALLS AND LIMITATIONS OF STUDIESPERFORMED IN LIVER CIRRHOSIS ASCITES; Experimental Animal Models; Etiology; Sample Size and Clinical Stage Variability among Patients; Healthy Control Reference; CONCLUSION; REFERENCES; Chapter 2: DIFFERENCES IN THE INFLAMMATORY STATUS DERIVED ON AETIOLOGY IN HUMAN LIVER CIRRHOSIS; ABSTRACT; INTRODUCTION; NATURAL HISTORY OF LIVER CIRRHOSIS; AETIOLOGY OF CIRRHOSIS; THE DEVELOPMENT OF ASCITES INDUCEDBY LIVER CIRRHOSIS; BACTERIAL TRANSLOCATION IN LIVER CIRRHOSIS INFLAMMATORY STATUS IN ASCITESOF DECOMPENSATED LIVER CIRRHOSISSTUDIES COMPARING HCV- VSALCOHOL-INDUCED CIRRHOSIS; DIFFERENCES BETWEEN THE PERITONEAL INFLAMMATORY STATUS IN CIRRHOTIC ASCITES INDUCED BY ALCOHOL AND HCV INFECTION; CONCLUSION; REFERENCES; Chapter 3: MINIMALLY INVASIVE MANAGEMENT OF REFRACTORY MALIGNANT ASCITES; ABSTRACT; 1. INTRODUCTION; 2. CAUSES OF REFRACTORY MALIGNANT ASCITES; A. Mechanisms of Production; 3. MINIMALLY INVASIVE MANAGEMENT OF REFRACTORYMALIGNANT ASCITES; A. Historical Background; B. Indications; C. Contraindications; D. Devices; I. Peritoneal Tunneled Catheters INTRODUCTION1. ASCITES; 1.1. Definition of Ascites; 1.2. Malignant Ascites in Ovarian Cancer; 1.3. Management of Malignant Ascites in Ovarian Cancer; 1.3.1. Non-Molecular Therapy; 1.3.1.1. Paracentesis; 1.3.1.2. Catheter Drainage; 1.3.1.3. Diuretic Therapy; 1.3.1.4. Concentrated Ascites Reinfuision Therapy (CART); 1.3.2. Molecular Therapy; 1.3.2.1. Catumaxomab; 1.3.2.2. Anti-Angiogenesis Treatment; 2. ROLE OF MALIGNANT ASCITES IN OVARIAN CANCER; 2.1. Dissemination; 2.1.1. Routes of Dissemination; 2.1.2. Ascites as a Carrier; 2.2. Angiogenesis; 2.2.1. General Information PleurX Drainage System (Figure 1)Aspira® Drainage System (Figure 2); II. Peritoneal Ports; E. Technique; I. Peritoneal Tunneled Catheters; Pre-Procedure Preparation; Intra-Procedure Preparation; Tunneled Catheter Placement Using Ultrasound and FluoroscopicGuidance; Drainage; II. Peritoneal Ports; Pre-Procedure Preparation; Intra-Procedure Preparation; Peritoneal Port Placement Using Ultrasound and FluoroscopicGuidance; Drainage; F. Potential Complications; 4. OUTCOMES; CONCLUSION; REFERENCES; Chapter 4: A LOOK AT THE MANAGEMENT AND USAGE OF MALIGNANT ASCITES IN OVARIAN CANCER; ABSTRACT